首页> 美国卫生研究院文献>Arthritis Research >Safety tolerability pharmacokinetics and pharmacodynamics of PF-06650833 a selective interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor in single and multiple ascending dose randomized phase 1 studies in healthy subjects
【2h】

Safety tolerability pharmacokinetics and pharmacodynamics of PF-06650833 a selective interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor in single and multiple ascending dose randomized phase 1 studies in healthy subjects

机译:PF-06650833(一种选择性白介素-1受体相关激酶4(IRAK4)抑制剂)在健康受试者的单次和多次递增剂量随机1期研究中的安全性耐受性药代动力学和药效学

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Design and PF-06650833 final dosing scheme in study 1 (SAD) and study 2 (MAD). PK and PD sampling time was up to 96 h for cohorts 1 and 2. Subjects in cohorts 3 and 4 were followed up to day 21 of the final period to better characterize the terminal phase, given the potentially long elimination half-life based on emerging data. Dose administered after consumption of a high-fat breakfast meal. Alternate IR formulation. Cohort 3 consisted of only four periods, and cohort 4 consisted of only two periods that were separated by 14 days, in order to maintain the overall predicted exposure in an individual subject to ≤ 28 days. In study 1, within each period, 8 subjects were randomized to receive PF-06650833 and 2 subjects were randomized to receive placebo. All subjects within a cohort received one or more doses of PF-06650833 and/or placebo. Doses were escalated sequentially within each period, based on evaluation of ≥ 48 h of safety and tolerability for all subjects and ≥ 8 h of PK data for at least 6 subjects receiving PF-06650833 and 1 subject receiving placebo. All doses were administered orally under fasting conditions (overnight fast of ≥ 10 h) unless otherwise indicated. In study 2, within each cohort, eight subjects were planned to receive PF-06650833 and 2 subjects were planned to receive placebo. All doses were administered orally under standard (not high-fat) meal, fed conditions. QD doses were 24 h apart, BID doses were 12 h apart, TID doses were 8 h apart, and QID doses were 6 h apart. When dosing in the fed condition, the morning and evening doses were administered within 5 min of completing the standard meal. twice daily; immediate-release: multiple ascending doses; modified-release; pharmacokinetics; once daily; four times per day; single ascending doses; three times per day
机译:研究1(SAD)和研究2(MAD)的设计和PF-06650833最终剂量方案。队列1和队列2的PK和PD采样时间最长为96 h。队列3和队列4的对象被追踪到最后一个阶段的第21天,以更好地表征末期,因为基于新出现的方法可能具有较长的消除半衰期数据。食用高脂早餐后服用的剂量。替代IR配方。同类群组3仅由四个时段组成,而同类群组4仅由两个间隔14个工作日的时段组成,以使单个受试者的总体预测暴露量≤28个工作日。在研究1中,每个时期内,有8名受试者被随机分配接受PF-06650833,有2名受试者被随机分配接受安慰剂。队列中的所有受试者均接受一剂或多剂PF-06650833和/或安慰剂。根据对至少6名接受PF-06650833的受试者和1名接受安慰剂的受试者的所有受试者的安全性和耐受性≥48h和PK数据的≥8h的评估,每个时期内的剂量依次递增。除非另有说明,否则所有剂量均在禁食条件下(≥10 h的整夜禁食)口服。在研究2中,每个队列中计划有8名受试者接受PF-06650833,并且计划有2名受试者接受安慰剂。所有剂量均在标准(非高脂)餐,进食条件下口服。 QD剂量相距24 h,BID剂量相距12 h,TID剂量相距8 h,QID剂量相距6 h。在喂食条件下给药时,在完成标准餐后5分钟内进行早晚剂量。每天两次;立即释放:多次上升剂量;修改版本;药代动力学每天一次;每天四次;单次上升剂量;每天三回

著录项

相似文献

  • 外文文献
  • 中文文献
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号